Rationale and design
Olde Nordkamp LR, Knops RE, Bardy GH, et al. Rationale and design of the PRAETORIAN trial: a Prospective, RAndomizEd comparison of subcuTaneOus and tRansvenous ImplANtable cardioverter-defibrillator therapy. Am Heart J. 2012;163(5):753-760.e2. doi:10.1016/j.ahj.2012.02.012
Primary publication
Knops RE, Olde Nordkamp LRA, Delnoy PHM, et al. Subcutaneous or Transvenous Defibrillator Therapy. N Engl J Med. 2020;383(6):526-536. doi:10.1056/NEJMoa1915932
The New England Journal of Medicine (August 6, 2020):
Results of the PRAETORIAN study were presented as a late breaking clinical trial at the Heart Rhythm Society (HRS) 2020 conference. Watch below the presentation.
Secondary publications
Knops RE, van der Stuijt W, Delnoy PPHM, et al. Efficacy and Safety of Appropriate Shocks and Antitachycardia Pacing in Transvenous and Subcutaneous Implantable Defibrillators: Analysis of All Appropriate Therapy in the PRAETORIAN Trial. Circulation. 2022;145(5):321-329. doi:10.1161/CIRCULATIONAHA.121.057816
Knops RE, Pepplinkhuizen S, Delnoy PPHM, et al. Device-related complications in subcutaneous versus transvenous ICD: a secondary analysis of the PRAETORIAN trial. Eur Heart J. 2022;43(47):4872-4883. doi:10.1093/eurheartj/ehac496
Knops RE, de Veld JA, Ghani A, et al. Quality of Life in Subcutaneous or Transvenous Implantable Cardioverter-Defibrillator Patients: A Secondary Analysis of the PRAETORIAN Trial. Circ Cardiovasc Qual Outcomes. 2024;17(11):e010822. doi:10.1161/CIRCOUTCOMES.124.010822
Olde Nordkamp LRA, Pepplinkhuizen S, Ghani A, et al. Inappropriate Therapy and Shock Rates Between the Subcutaneous and Transvenous Implantable Cardiac Defibrillator: A Secondary Analysis of the PRAETORIAN Trial. Circ Arrhythm Electrophysiol. 2024;17(12):e012836. doi:10.1161/CIRCEP.124.012836